Article

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.

University of Michigan Hospital, Ann Arbor 48109-0366, USA.
Journal of the American College of Cardiology (Impact Factor: 15.34). 12/1995; 26(5):1133-9. DOI: 10.1016/0735-1097(95)00301-0
Source: PubMed

ABSTRACT This study was designed to evaluate the effect of pravastatin on progression of coronary atherosclerosis and ischemic events in patients with coronary artery disease and mild to moderate hyperlipidemia.
Few clinical trial data support the use of lipid-lowering therapy in patients with coronary artery disease and mild to moderate elevations in cholesterol levels.
Four hundred eight patients (mean age 57 years) with coronary artery disease and low density lipoprotein (LDL) cholesterol > or = 130 mg/dl (3.36 mmol/liter) but < 190 mg/dl ([4.91 mmol/liter]) despite diet were randomized in a 3-year study to receive pravastatin or placebo. Atherosclerosis progression was evaluated by quantitative coronary arteriography.
Baseline mean LDL cholesterol was 164 mg/dl (4.24 mmol/liter). Pravastatin decreased total and LDL cholesterol and triglyceride levels by 19%, 28% and 8%, respectively, and increased high density lipoprotein cholesterol by 7% (p < or = 0.001 vs. placebo for all lipid variables). Progression of atherosclerosis was reduced by 40% for minimal vessel diameter (p = 0.04), particularly in lesions < 50% stenosis at baseline. There was a consistent although not statistically significant effect on mean diameter and percent diameter stenosis. There were also fewer new lesions in those assigned pravastatin (p < or = 0.03). Myocardial infarction was reduced during active treatment (8 in the pravastatin group, 17 in the placebo group; log-rank test, p < or = 0.05; 60% risk reduction), with the benefit beginning to emerge after 1 year.
In patients with coronary artery disease and mild to moderate cholesterol elevations, pravastatin reduces progression of coronary atherosclerosis and myocardial infarction. The time course of event reduction increases the potential for a relatively rapid decrease in the clinical manifestations of coronary artery disease with lipid lowering.

0 Bookmarks
 · 
88 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is psychological and socioeconomic problems as well as health problems related to physical disease and disorder. The obesity epidemic, including a marked increase in the prevalence of obesity among pregnant women, represents a critical public health problem throughout the world. Gung-Gui-Tang (GGT), a prescription of traditional Korean medicine, has been used to treat dizziness due to loss of blood as well as static blood after childbirth. However, the therapeutic potential of GGT on postpartum obesity has not been fully elucidated in an experimental model. In our research, GGT inhibited the increases of body weight and adipose tissues in postpartum mice fed a high-fat diet. GGT also inhibited the elevations of plasma lipid profiles such as triglyceride, low-density lipoprotein cholesterol, total cholesterol, and glutamate pyruvate transaminase. Overall, these results provide evidence that GGT can help to inhibit postpartum obesity and open new perspective to recover the shape of mother into the moment of conception.
    TANG. 08/2012; 2(3).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La nécrose myocardique est le principal critère de morbidité cardiaque post-opératoire. Sa nouvelle définition introduite récemment par l'American Heart Association [1] prend en compte toutes les élévations de bio-marqueurs cardiaques au-dessus des seuils de détection. Durant la phase post-opératoire, l'association entre les taux plasmatiques de troponine I cardiaque et la mortalité à court [2, 3], moyen [4] et long terme [5] est maintenant bien établie. Le diagnostic de nécrose myocardique post-opératoire peut donc se résumer au simple dosage de ce marqueur [1]. Outre le fait que cette nouvelle définition modifie les données épidémiologiques usuelles, il est important de constater que ce nouveau cadre nosographique regroupe plusieurs mécanismes physiopathologiques relevant de stratégies thérapeutiques différentes. Si la revascularisation demeure le principal objectif thérapeutique en cas d'obstruction du tronc coronaire, l'attitude thérapeutique face à des nécroses myocardiques survenant en l'absence de thrombose reste moins consensuelle. Ces formes de nécroses sont néanmoins les plus fréquentes durant la phase post-opératoire [6]. La place du contrôle des déterminants des apports et de la consommation myocardique en oxygène reste importante dans toutes les situations [7], elle ne prévient toutefois pas la nécrose myocardique de manière complète. La survenue de nécroses myocardiques en absence de thrombose coronaire et malgré le contrôle de ces facteurs motive l'utilisation de traitements capables de restaurer l'autorégulation du débit coronaire. Parmi les molécules suscep-tibles d'être actives, les statines améliorent de manière très importante la vasomotricité coronaire chez le sujet athérosclérotique, hypercholestérolé-mique [8] ou non [9]. Correspondance : Département Anesthésie-Réanimation, Hôpital Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris, France, e-mail : Yannick.Le-Manach@wanadoo.fr 101 102 Physiopathologie de la nécrose myocardique post-opératoire Les mécanismes physiopathologiques impliqués dans la nécrose myocardique post-opératoire peuvent être divisés en deux catégories [7, 10]. La nécrose myocardique à flux coronaire normal (high flow) s'oppose à la nécrose myocardique à flux coronaire altéré (low flow), pour laquelle le réseau vasculaire coronaire est modifié de manière prolongée ou non.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypertension (HT) and prehypertension (preHT) were independent predictors of cardiovascular diseases. Urinary albumin leakage is a manifestation of generalized vascular damage. B-type natriuretic peptide (BNP) is a vasoactive peptide secreted by left ventricle in response to myocytic stretch. We aimed to investigate relationship between microalbuminuria (MA) and BNP in untreated elevated blood pressures. Of 105 untreated prehypertensive subjects (53 men, 52 women), 100 hypertensive subjects (51 men, 49 women) and 57 normotensive subjects (32 men, 25 women) none had history of diabetes. Urine albumin excretion was measured by immunoradiometric assay in morning urine sample. The prevalence of MA was higher in hypertensive group than in prehypertensive group and in normotensive group (Hypertensive group; 33.9%, prehypertensive; 25.9%, normotensive; 10%). Subjects with HT had higher prevalence of microalbminuria; larger body mass index, higher levels of triglycerides, blood glucose and creatinin were more common in subjects with HT than in those with preHT. In hypertensive group; patients with microalbuminuria had higher systolic blood pressure (SBP), BNP, LVMI and lower eGFR as compared to those without MA. MA was significantly correlated with LVMI, BNP and SBP. In multivariate regression analysis, SBP (β: 0.361; P < 0.001), LVMII (β: 0.267; P = 0.011) and BNP (β: 0.284; P = 0.005) were independent variables associated with MA in hypertensives. In prehypertensive group; patients with microalbuminuria had higher SBP, BNP, LVMI and lower eGFR as compared to those without MA. MA was significantly correlated with LVMI, BNP and SBP. In multivariate regression analysis, SBP (β: 0.264; P = 0.002), LVMI (β: 0.293; P = 0.001) and BNP (β: 0.168; P = 0.045) were associated with MA in prehypertensives. In preHT and HT, SBP, BNP and LVMI are associated with MA. In the evaluation of increased blood pressures, in case of increased BNP and LVMI, MA should be investigated even in prehypertensive stages. The subjects with increased blood pressures should get medical treatment to prevent the effects on vascular structure and myocardium even in prehypertensive phase.
    International Journal of Clinical and Experimental Medicine 10/2014; 7(10):3420-3429. · 1.42 Impact Factor

Preview

Download
0 Downloads
Available from